Biodesix
Founded Year
2005Stage
IPO | IPOTotal Raised
$259.21MDate of IPO
10/28/2020Market Cap
0.07BStock Price
1.60About Biodesix
Biodesix (NASDAQ: BDSX) is a fully integrated molecular diagnostics company advancing the development of products for personalized medicine. Biodesix develops, validates, and commercializes VeriStrat, a serum proteomic test currently available to help physicians guide therapy for patients with advanced non-small-cell lung cancer.
Biodesix Headquarter Location
2970 Wilderness Place Suite 100
Boulder, Colorado, 80301,
United States
303-417-0500
Research containing Biodesix
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Biodesix in 2 CB Insights research briefs, most recently on Mar 12, 2020.
Mar 12, 2020
100+ Of The Most Well-Funded Medical Device Startups
Expert Collections containing Biodesix
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Biodesix is included in 5 Expert Collections, including Cancer.
Cancer
3,710 items
Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'
Medical Devices
7,911 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Omics
1,265 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Health Monitoring & Diagnostics
76 items
Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx
Health IT
7,900 items
Biodesix Patents
Biodesix has filed 51 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Classification algorithms
- Experimental cancer drugs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/18/2017 | 12/7/2021 | Molecular biology, Rare diseases, Inflammations, Transcription factors, Syndromes | Grant |
Application Date | 8/18/2017 |
|---|---|
Grant Date | 12/7/2021 |
Title | |
Related Topics | Molecular biology, Rare diseases, Inflammations, Transcription factors, Syndromes |
Status | Grant |
Latest Biodesix News
May 12, 2022
BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus...
Biodesix Web Traffic
Biodesix Rank
You May Also Like
ProteoGenix offers maternal-fetal diagnostics
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.
AngioLogix is a provider of cardiovascular health diagnostics.
LabNow has developed the LabNow System to conduct healthcare-related diagnostics at the point-of-care.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.